Categories: Wire Stories

Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, �Meiji”) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, “Dong-A”).

DMB-3115 is a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of patients with several inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Meiji and Dong-A are co-developing DMB-3115 under the strategic collaboration partnership agreement on biosimilars signed in September 2011. DMB-3115 is produced by using Sp2/0 cells, the same as those used in reference products to achieve high similarity in quality aspects.

The Phase I clinical trial is a randomized double-blind, three-arm, single-dose study to compare pharmacokinetics, safety and tolerability of DMB-3115 with its reference products (US- and EU-marketed products) in 296 healthy volunteers at a single site in Europe. As a result, bioequivalence of DMB-3115 compared to reference products was demonstrated in terms of several pharmacokinetic parameters. A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab. There were no new unexpected adverse events.

The Phase III multi-regional clinical trials in patients with plaque psoriasis, with the target number of patient being 590, has been initiated in Europe and the United States. In this study, efficacy, safety, pharmacokinetics and immunogenicity of DMB-3115 and reference products (45 mg or 90 mg subcutaneous injection, respectively) are being compared in randomized, double-blinded controlled trial.

Meiji aims to contribute to medical care and society by developing and launching biosimilars with high quality as well as biologics products.

Contacts

Meiji Seika Pharma Co., Ltd.

Sho Takahata, Ph.D.

Group Manager

Licensing and Product Acquisition

Partnering Strategy and Business Development Dept.

Telephone: +81-70-2464-5045

E-mail : m-biocmo@meiji.com

Alex

Recent Posts

Sahm Capital Joins the Arab Federation of Capital Markets (AFCM)

RIYADH, SAUDI ARABIA - Media OutReach Newswire - 16 March 2025 - Sahm Capital is…

4 hours ago

UU Wallet Secures U.S. MSB License, Embarking on a New Chapter of Global Compliance with Security at Its Core

HONG KONG SAR - Media OutReach Newswire - 14 March 2025 - UU Wallet, a…

2 days ago

KVB Wins the Most Popular Broker 2024 Award – Rising Above 300+ Brokers

HANOI, VIETNAM - Media OutReach Newswire - 14 March 2025 – KVB emerged as the…

2 days ago

High Marks for Hong Kong’s University Degree Courses

HONG KONG SAR - Media OutReach Neswire - 14 March 2025 - Hong Kong has…

2 days ago

Calling Global Startups! EPIC 2025 Opens Application with US$100M Investment Up for Grabs

HONG KONG SAR - Media OutReach Newswire - 14 March 2025 – Hong Kong Science…

2 days ago

British Council East Asia Education Week 2025 Strengthening UK-East Asia higher education partnerships

UK Vice-Chancellors, UK alumni and East Asia leaders convene in Hong Kong to shape the…

2 days ago